1.34 USD
▼-0.07-5.32%
盘后 1.58 0.00%
2026-09-16
市值
$3.25M
市盈率
—
EPS
-1.77
股息率
—
52 周区间
1.32 – 4.59
成交量
33.71K
Beta
-0.97
目标价
—
52W 低 1.3252W 高 4.59
价格走势
公司简介
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.